[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100548743":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":34,"collaborators":7,"id":37,"slug":7,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":7,"eligibilityCriteria":41,"healthyVolunteers":38,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":7,"studyType":48,"phases":7,"briefSummary":49,"conditions":50,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"Belgian Research on AIDS and HIV Consortium","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Stéphane De Wit, MD\u002FPhD","Belgian Research on AIDS & HIV Consortium","PRINCIPAL_INVESTIGATOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Rakan Nasreddine, MD","CONTACT","+32 2 535 4130","rakan.nasreddine@stpierre-bru.be",[20],{"facility":21,"status":22,"city":23,"state":7,"zip":7,"country":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Saint-Pierre University Hospital","RECRUITING","Brussels","Belgium",{"type":26,"coordinates":27},"Point",[28,29],4.34878,50.85045,{"lat":29,"lon":28},[32],{"name":33,"role":16,"phone":7,"phoneExt":7,"email":7},"Stéphane De Wit",{"type":12,"investigatorFullName":35,"investigatorTitle":36,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Rakan Nasreddine","Head of Research","100548743",false,"NCT06424964","Use of Long-Acting Injectable Cabotegravir\u002FRilpivirine for the Treatment of HIV in Belgium","Inclusion Criteria:\n\n* HIV-1 patients, aged 18 years and above, having received at least 1 dose of LAI CAB\u002FRPV between September 1, 2021, and March 31, 2024.","ALL","18 Years","99 Years",{"count":46,"type":47},600,"ESTIMATED","OBSERVATIONAL","This will be a multi-center, single arm observational cohort study with an assessment of patient-reported outcomes (PROs) and of clinical and virologic outcomes.\n\nPrimary outcome • Evaluate patient perception of, and satisfaction with, long-acting injectable (LAI) cabotegravir\u002Frilpivirine (CAB\u002FRPV) for the treatment of HIV\n\nSecondary outcomes\n\n• Description of the demographic, HIV-, and non-HIV-related characteristics of participants included in this analysis",[51],"Human Immunodeficiency Virus","2025-02-04",{"date":54,"type":55},"2025-02-05","ACTUAL",{"date":57,"type":55},"2025-01-13",{"date":59,"type":47},"2025-07",{"name":5,"class":6},1]